NO20084593L - Okulaere allergibehandlinger - Google Patents

Okulaere allergibehandlinger

Info

Publication number
NO20084593L
NO20084593L NO20084593A NO20084593A NO20084593L NO 20084593 L NO20084593 L NO 20084593L NO 20084593 A NO20084593 A NO 20084593A NO 20084593 A NO20084593 A NO 20084593A NO 20084593 L NO20084593 L NO 20084593L
Authority
NO
Norway
Prior art keywords
ocular allergy
allergy treatments
treatments
ocular
alkaftadine
Prior art date
Application number
NO20084593A
Other languages
English (en)
Other versions
NO341147B1 (no
Inventor
Jagdish Parasrampuria
Avner Ingerman
Frans Janssens
Anton Megens
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084593(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Publication of NO20084593L publication Critical patent/NO20084593L/no
Publication of NO341147B1 publication Critical patent/NO341147B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sammensetninger, kit og fremgangsmåter for behandling eller hindring av okulære allergier og inflammasjon og symptomer derav som innbefatter alkaftadin eller et farmasøytisk akseptabelt salt derav.
NO20084593A 2006-03-31 2008-10-29 Alkaftadin samt oftalmisk sammensetning for anvendelse i behandling av okulær allergi og et kit NO341147B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19
PCT/US2007/064911 WO2007117971A2 (en) 2006-03-31 2007-03-26 Ocular allergy treatments

Publications (2)

Publication Number Publication Date
NO20084593L true NO20084593L (no) 2008-10-29
NO341147B1 NO341147B1 (no) 2017-09-04

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084593A NO341147B1 (no) 2006-03-31 2008-10-29 Alkaftadin samt oftalmisk sammensetning for anvendelse i behandling av okulær allergi og et kit

Country Status (30)

Country Link
US (7) US8664215B2 (no)
EP (2) EP2004196B1 (no)
JP (3) JP5292277B2 (no)
KR (1) KR101321731B1 (no)
CN (1) CN102895234A (no)
AR (1) AR060278A1 (no)
AU (1) AU2007234957B2 (no)
BR (1) BRPI0710085B8 (no)
CA (1) CA2648115C (no)
CL (1) CL2007000916A1 (no)
CR (1) CR10414A (no)
DK (2) DK3150209T3 (no)
EA (1) EA016221B1 (no)
EC (1) ECSP088786A (no)
ES (2) ES2752823T3 (no)
HK (1) HK1131331A1 (no)
IL (1) IL194473A (no)
JO (1) JO3358B1 (no)
MX (1) MX2008012657A (no)
MY (1) MY153669A (no)
NI (1) NI200800261A (no)
NO (1) NO341147B1 (no)
NZ (1) NZ571690A (no)
PE (1) PE20080053A1 (no)
PL (2) PL2004196T3 (no)
SG (1) SG170044A1 (no)
TW (2) TWI578990B (no)
UY (1) UY30254A1 (no)
WO (1) WO2007117971A2 (no)
ZA (1) ZA200809327B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3150209T3 (da) 2006-03-31 2019-10-28 Vistakon Pharmaceuticals Llc Okulære allergibehandlinger
AU2007243334A1 (en) 2006-04-26 2007-11-08 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling
JP2011503061A (ja) * 2007-11-08 2011-01-27 アーシエックス セラピューティックス， インコーポレイテッド 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
ES2910374T3 (es) 2009-03-17 2022-05-12 Nicox Ophthalmics Inc Formulaciones oftálmicas de cetirizina y procedimientos de uso
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US9409913B2 (en) * 2012-11-21 2016-08-09 Enaltec Labs Private Limited Polymorphic forms of alcaftadine
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
MX2019001633A (es) 2016-08-12 2019-09-18 Silk Tech Ltd Proteina derivada de la seda para el tratamiento de la inflamacion.
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
WO2019026992A1 (ja) * 2017-08-03 2019-02-07 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
CN111727035B (zh) * 2018-01-18 2024-05-28 费斯制药股份有限公司 包含比拉斯汀、β-环糊精和至少一种胶凝剂的眼用组合物
JP2023530166A (ja) 2020-06-15 2023-07-13 アルケム・ラボラトリーズ・リミテッド アルカフタジンとコルチコステロイドの組み合わせ
EP4312973A1 (en) 2021-04-01 2024-02-07 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
WO2024010044A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物
WO2024010039A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
JPH089616B2 (ja) * 1990-10-10 1996-01-31 シェリング・コーポレーション 置換されたイミダゾベンズアゼピン類およびイミダゾピリドアゼピン類
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
KR20150017002A (ko) 2006-03-17 2015-02-13 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 눈용 조성물
DK3150209T3 (da) 2006-03-31 2019-10-28 Vistakon Pharmaceuticals Llc Okulære allergibehandlinger

Also Published As

Publication number Publication date
PL2004196T3 (pl) 2017-01-31
ES2594655T3 (es) 2016-12-21
JP2009533333A (ja) 2009-09-17
CA2648115C (en) 2015-03-24
US20120094978A1 (en) 2012-04-19
US20140107102A1 (en) 2014-04-17
US20210030762A1 (en) 2021-02-04
EA016221B1 (ru) 2012-03-30
JP6039716B2 (ja) 2016-12-07
US20240058355A1 (en) 2024-02-22
CR10414A (es) 2009-02-23
TWI578990B (zh) 2017-04-21
MX2008012657A (es) 2009-02-19
IL194473A (en) 2016-04-21
NO341147B1 (no) 2017-09-04
SG170044A1 (en) 2011-04-29
IL194473A0 (en) 2009-08-03
NZ571690A (en) 2011-09-30
TW201446249A (zh) 2014-12-16
CL2007000916A1 (es) 2008-01-25
AR060278A1 (es) 2008-06-04
JP2013144703A (ja) 2013-07-25
WO2007117971A2 (en) 2007-10-18
KR20080110881A (ko) 2008-12-19
TWI450721B (zh) 2014-09-01
ES2752823T3 (es) 2020-04-06
JO3358B1 (ar) 2019-03-13
JP5292277B2 (ja) 2013-09-18
NI200800261A (es) 2012-10-30
EP3150209B1 (en) 2019-07-24
HK1131331A1 (en) 2010-01-22
EP3150209A1 (en) 2017-04-05
EP2004196A2 (en) 2008-12-24
UY30254A1 (es) 2007-08-31
MY153669A (en) 2015-03-13
US8664215B2 (en) 2014-03-04
PE20080053A1 (es) 2008-03-10
US20080051385A1 (en) 2008-02-28
US20170065605A1 (en) 2017-03-09
BRPI0710085A2 (pt) 2011-08-23
CA2648115A1 (en) 2007-10-18
US20230181594A1 (en) 2023-06-15
AU2007234957B2 (en) 2012-12-13
ECSP088786A (es) 2009-01-30
CN102895234A (zh) 2013-01-30
BRPI0710085B1 (pt) 2019-12-17
TW200815016A (en) 2008-04-01
EA200870396A1 (ru) 2009-04-28
KR101321731B1 (ko) 2013-10-30
US10617695B2 (en) 2020-04-14
AU2007234957A1 (en) 2007-10-18
PL3150209T3 (pl) 2020-03-31
WO2007117971A3 (en) 2007-12-27
ZA200809327B (en) 2009-12-30
DK3150209T3 (da) 2019-10-28
DK2004196T3 (en) 2016-09-05
JP2015131820A (ja) 2015-07-23
EP2004196B1 (en) 2016-06-29
BRPI0710085B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NO20084593L (no) Okulaere allergibehandlinger
WO2009026334A3 (en) Treatment with kallikrein inhibitors
WO2007089445A3 (en) Ang2 and vegf inhibitor combinations
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
TR201818983T4 (tr) İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
NO20082191L (no) Forbindelser
TR200504892A1 (tr) Belirti göstermeyen tüberküloz tedavisi
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
NO20081042L (no) PPAR aktive forbindelser
MA32934B1 (fr) Combinaisons inhibitrices hsp90
CL2008001457A1 (es) Compuestos derivados de 6-(piridin-3-il)quinolina, inhibidores de la pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer en un humano que lo necesite.
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX2009006505A (es) Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para usarlas en el tratamiento de la presbiopia.
WO2009075882A3 (en) Impaired wound healing compositions and treatments
AR059330A1 (es) Composiciones acondicionadoras del cabello
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
WO2005108416A3 (en) Myosin light chain kinase inhibitors and their use
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
NO20090724L (no) Benzylaminer, fremgangsmåte for fremstilling av slike, og anvendelse av dem som betennelseshemmende midler
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
DK1994005T3 (da) Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: JOHNSON & JOHNSON VISION CARE, US